Bolt Biotherapeutics, Inc.: net income or loss
Net income or loss for Bolt Biotherapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Bolt Biotherapeutics, Inc. financial histories
What this measure means
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -33,376,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104121 |
| 2024-01-01 | 2024-12-31 | -63,118,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104121 |
| 2023-01-01 | 2023-12-31 | -69,197,000 | USD | 2025-03-24 | 10-K · 0000950170-25-043873 |
| 2022-01-01 | 2022-12-31 | -88,098,000 | USD | 2024-03-21 | 10-K · 0000950170-24-034692 |
| 2021-01-01 | 2021-12-31 | -98,591,000 | USD | 2023-03-29 | 10-K · 0000950170-23-010613 |
| 2020-01-01 | 2020-12-31 | -60,728,000 | USD | 2022-03-30 | 10-K · 0000950170-22-005047 |
Related financial histories
- Bolt Biotherapeutics, Inc.: total assets
- Bolt Biotherapeutics, Inc.: total liabilities
- Bolt Biotherapeutics, Inc.: stockholders equity
- Bolt Biotherapeutics, Inc.: cash and cash equivalents
- Bolt Biotherapeutics, Inc.: operating cash flow
- Bolt Biotherapeutics, Inc.: capital expenditure payments
- Bolt Biotherapeutics, Inc.: revenue
- Bolt Biotherapeutics, Inc.: financing cash flow
- Bolt Biotherapeutics, Inc.: investing cash flow
- Bolt Biotherapeutics, Inc.: retained earnings or deficit
- Bolt Biotherapeutics, Inc.: basic weighted-average shares
- Bolt Biotherapeutics, Inc.: diluted weighted-average shares
- Bolt Biotherapeutics, Inc.: basic earnings per share
- Bolt Biotherapeutics, Inc.: diluted earnings per share
- Bolt Biotherapeutics, Inc.: net property, plant and equipment
- Bolt Biotherapeutics, Inc.: share-based compensation expense
- Bolt Biotherapeutics, Inc.: operating income or loss
- Bolt Biotherapeutics, Inc.: current assets
- Bolt Biotherapeutics, Inc.: current liabilities
- Bolt Biotherapeutics, Inc.: current accounts payable
- Bolt Biotherapeutics, Inc.: operating expenses
- Bolt Biotherapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Bolt Biotherapeutics, Inc. / CIK 0001641281
- Captured
- 2026-09-21T17:22:27.349Z
- SEC response SHA-256
0f6383c139bc967418d7cb627e00bbaa74f12b147973818c18daaed16688a891
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001641281.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))